Professor Mariam Jamal-Hanjani has been officially appointed as the new Chief Clinician at Cancer Research UK, stepping into a prominent leadership position tasked with guiding the charity’s clinical research strategy and spearheading ongoing efforts to revolutionize cancer treatment and patient care.
In her new capacity, Professor Jamal-Hanjani will play a pivotal role in shaping how the organization approaches clinical research, helping to direct funding, resources, and scientific collaboration toward the most promising avenues of oncology. Her appointment marks a significant transition for the prominent charity, as she takes over the responsibilities previously managed by her predecessor.
An Internationally Recognized Authority in Cancer Genomics
Beyond her new leadership responsibilities with Cancer Research UK, Professor Jamal-Hanjani serves as a Professor of Cancer Genomics and Metastasis at University College London (UCL). She is widely regarded as an internationally recognized researcher whose work focuses primarily on the complex mechanisms of how cancer evolves, spreads throughout the body, and develops resistance to conventional and advanced medical treatments.
Her extensive academic and clinical background has positioned her at the forefront of modern oncology. By studying the genetic and molecular changes that occur within tumors over time, Professor Jamal-Hanjani and her research teams have sought to unlock fundamental answers regarding the unpredictable nature of cancer progression. Understanding these biological pathways is considered vital for the scientific community, as it sheds light on why certain malignancies manage to evade therapy and why some patients experience disease recurrence even after initial successful interventions.
Pioneering Research into Lung Cancer and Tumor Evolution
A major cornerstone of Professor Jamal-Hanjani’s scientific career involves ground-breaking studies investigating lung cancer. Lung cancer remains one of the most challenging diagnoses in modern medicine, largely due to the intricate ways in which tumors change, adapt, and mutate as the disease progresses.
Her research has helped scientists gain a much clearer understanding of the timeline and mechanics of tumor evolution. By mapping out how cancer cells diversify within a single tumor and spread to other parts of the body, her work provides critical insights into why certain types of cancer become increasingly difficult to treat as time goes on. These insights are not only academic; they hold the immense potential to pave the way for the development of more personalized and targeted treatments, ultimately aiming to secure better survival rates and long-term outcomes for patients facing difficult cancer diagnoses.
Leadership and Vision for the Future
The leadership at Cancer Research UK has expressed immense enthusiasm regarding Professor Jamal-Hanjani’s appointment. Michelle Mitchell, the Chief Executive of Cancer Research UK, highlighted the exceptional expertise and leadership qualities that Professor Jamal-Hanjani brings to the role, emphasizing her proven track record in guiding multidisciplinary scientific efforts.
Reflecting on the appointment, Michelle Mitchell noted that Professor Jamal-Hanjani brings deep experience in leading high-performing research teams capable of delivering radical new insights into the complex behaviors of cancer. These insights include understanding how tumors grow, spread, resist therapies, and occasionally return after treatment, all of which are critical areas of focus for the charity’s overarching mission.
Upon officially stepping into the role, Professor Jamal-Hanjani shared her thoughts on the honor of leading the charity’s clinical research initiatives. She noted that Cancer Research UK possesses an extraordinary and enduring track record of translating laboratory discoveries and scientific breakthroughs into tangible, real-world benefits for patients. She expressed that the opportunity to help shape and guide that vital mission is a responsibility she feels deeply privileged to undertake.
Furthermore, Professor Jamal-Hanjani emphasized her determination to accelerate the pace at which scientific research is translated into improved cancer outcomes for the general public. In discussing the pathway from discovery to patient care, she specifically highlighted the National Health Service (NHS) as a major institutional asset. She pointed out that the infrastructure of the NHS plays an indispensable role in connecting cutting-edge scientific discoveries directly with the patients who stand to benefit from them most.
A Notable Succession
Professor Jamal-Hanjani officially commenced her tenure as Chief Clinician in October 2026. In taking on this prestigious post, she succeeds Professor Charles Swanton, a renowned oncologist and researcher who held the position with distinction since 2017. Professor Swanton’s tenure was marked by significant advancements in the understanding of tumor evolution and cancer tracking, leaving behind a robust foundation for Professor Jamal-Hanjani to build upon as she charts the course for the next chapter of clinical research at Cancer Research UK.